Dr Ravandi talks to ecancertv about his highlights of ASH 2016.

He discusses his interest in acute myeloid leukaemia (AML), leukaemogenesis, the use of monoclonal antibody-based therapies, ALL, CLL, minimal residual disease monitoring and where he sees research heading in the future.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.